The ratings of five biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Keryx Biopharmaceuticals, Inc.’s (KERX) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Keryx Biopharmaceuticals focuses on developing and commercializing pharmaceuticals for the treatment of cancer and renal disease. In Portfolio Grader’s specific subcategories of Earnings Revisions, Equity and Cash Flow, KERX also gets an F. As of Feb. 3, 2015, 25.5% of outstanding Keryx Biopharmaceuticals, Inc. shares were held short. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. To get an in-depth look at KERX, get Portfolio Grader’s complete analysis of KERX stock.
Trius Therapeutics, Inc. (TSRX) is having a tough week. The company’s rating falls from a C to a D. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. For more information, get Portfolio Grader’s complete analysis of TSRX stock.
Vical Incorporated (VICL) experiences a ratings drop this week, going from last week’s C to a D. Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at VICL, get Portfolio Grader’s complete analysis of VICL stock.
Tenax Therapeutics, Inc. (TENX) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). The stock gets F’s in Earnings Momentum, Earnings Revisions and Equity. Cash Flow and Sales Growth also get F’s. The stock’s trailing PE Ratio is 110.00. For more information, get Portfolio Grader’s complete analysis of TENX stock.
Arrowhead Research Corporation (ARWR) gets weaker ratings this week as last week’s C drops to a D. Arrowhead Research, a biopharmaceutical company, develops targeted RNAi therapeutics in the United States. The stock gets F’s in Earnings Revisions, Equity and Cash Flow. As of Feb. 3, 2015, 25.5% of outstanding Arrowhead Research Corporation shares were held short. To get an in-depth look at ARWR, get Portfolio Grader’s complete analysis of ARWR stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
